Drug-induced liver injury associated with dacomitinib: A case report

Dacomitinib, the second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been used as a first-line treatment in non-small cell lung cancer (NSCLC) patients harboring EGFR mutation. In this case, we report a patient with drug-induced liver injury (DILI) associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xuanxuan, Huang, Anqi, Lu, Yun, Gao, Suyu, Hu, Wen, Cheng, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515502/
https://www.ncbi.nlm.nih.gov/pubmed/36185261
http://dx.doi.org/10.3389/fonc.2022.979462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515502/
https://www.ncbi.nlm.nih.gov/pubmed/36185261
http://dx.doi.org/10.3389/fonc.2022.979462

Ejemplares similares